MEREO BIOPHARMA GROUP PLC Acquisitiondate Fair Value Of Total Consideration Transferred
MEREO BIOPHARMA GROUP PLC (MREO) had Acquisitiondate Fair Value Of Total Consideration Transferred of GBP 1.09 million as of 2021-05-04, per its 20-F filed 2023-03-28.
Discontinued › Notes
ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred · last filed 2023-03-28
- 2021-05-04: Acquisitiondate Fair Value Of Total Consideration Transferred 1.09M GBP.
- 2019-04-23: Acquisitiondate Fair Value Of Total Consideration Transferred 40.89M GBP.
| Period end | Acquisitiondate Fair Value Of Total Consideration Transferred |
|---|---|
| 2021-05-04 | 1.09M GBP 20-F · filed 2023-03-28 |
| 2019-04-23 | 40.89M GBP 20-F · filed 2020-06-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |